NINDS CREATE Devices: Translational and Clinical Studies on the Path to 510(k) (UH2/UH3)

Sponsor: National Institute of Neurological Disorders and Stroke
Due Date: February 8, 2017 by 5 p.m. local time of applicant organization
Award: Budgets are not limited but must reflect the actual needs of the project. UH2 phase cost should rarely exceed $1,000,000 per year; UH3 phase costs should rarely exceed $1,500,000 per year. Total duration for UH2 and UH3 should not exceed 5 years.